Managing PCC Undertakings & Post‑notification Remedies in Philippine M&A (2026): Practical Guide for Buyers, Sellers & Advisers

Since the Philippine Competition Commission (PCC) raised its merger notification thresholds on 1 March 2026, setting the Size‑of‑Party (SOP) threshold at ₱9. 1 billion and the Size‑of‑Transaction (SOT) threshold at ₱3. 8 billion, the volume of compulsory filings has increased and enforcement scrutiny has intensified. For deal teams navigating merger control in the Philippines, knowing how to file is only half the challenge; the real complexity begins after notification, when the PCC evaluates competitive effects and decides whether to impose PCC undertakings in the Philippines as a condition of clearance. This guide provides a practitioner‑level playbook for managing post‑notification remedies, negotiating hold‑separate obligations, structuring conditional closings and drafting model clauses that protect both buyers and sellers through the clearance lifecycle.

It draws directly on the Philippine Competition Act (Republic Act No. 10667), the PCC Merger Procedure Rules and the PCC’s published guidelines for merger remedies.

Updated: 1 March 2026 thresholds (SOP ₱9.1 B / SOT ₱3.8 B)

In this guide you will find:

• A step‑by‑step breakdown of the post‑filing review process and realistic PCC clearance timelines.
• Three editable model clauses, behavioural undertaking, structural/divestiture commitment and hold‑separate arrangement, with drafting notes and negotiation levers.
• A practical remedy negotiation checklist covering pre‑filing, filing day, post‑filing priorities and closing.

Background: The PCC, the Philippine Competition Act & the March 2026 Threshold Change

The PCC is an independent quasi‑judicial government agency created under Republic Act No. 10667, also known as the Philippine Competition Act (PCA), enacted in 2015. It is tasked with promoting and maintaining market competition, preventing anti‑competitive conduct and reviewing mergers and acquisitions that could substantially prevent, restrict or lessen competition in any relevant market in the Philippines. Its jurisdiction extends to all entities operating in the country regardless of where a transaction is structured, and it has the statutory power to approve, conditionally approve or prohibit notifiable transactions under the PCA and its Implementing Rules and Regulations (IRR).

Under the compulsory notification regime, parties to a merger or acquisition must file a notification with the PCC before closing if the transaction meets the applicable thresholds. On 1 March 2026, the PCC adjusted these thresholds: the SOP threshold, measuring the aggregate annual gross revenues or total value of assets of the ultimate parent entity, was set at ₱9.1 billion, and the SOT threshold, measuring the value of the transaction itself, was set at ₱3.8 billion. Transactions that breach either threshold must be notified, and closing before clearance constitutes gun‑jumping, which carries significant penalties.

For deal teams, the practical effect of these changes is that more transactions now require foreign ownership and market‑entry analysis alongside a PCC filing strategy. Industry observers expect the increased filing volume to heighten the PCC’s focus on negotiating meaningful post‑notification remedies, and that makes understanding PCC undertakings in the Philippines essential for every M&A adviser operating in this jurisdiction.

What Happens After You File a PCC Merger Notification, Step by Step

Filing a PCC merger notification initiates a structured review process managed by the PCC’s Mergers and Acquisitions Office (MAO). Under the PCC Merger Procedure Rules, this process unfolds in distinct stages, each carrying timing implications that directly affect deal certainty and closing risk.

Intake and Completeness Check

On receipt of the notification form and all supporting documents, the MAO conducts a completeness assessment. If the filing is incomplete, the MAO issues a deficiency notice and the formal review clock does not start until the parties cure the deficiency. Common causes of incompleteness include missing market‑share data, incomplete competitor and customer lists, and unsigned officer certifications. Practitioners should treat the completeness check as a substantive hurdle: a well‑prepared submission with fully populated market definitions and supporting documentation can save weeks.

Initial Review (Phase I) and Provisional Remedies

Once the filing is accepted as complete, the PCC begins its initial (Phase I) review. During Phase I, the MAO examines the transaction’s competitive effects on the basis of the notification, publicly available data and any third‑party submissions. The statutory framework permits the PCC to clear the transaction outright, clear it subject to commitments or refer it to a full Phase II investigation. If the MAO identifies preliminary competition concerns during Phase I, it will typically engage the notifying parties in an informal dialogue about possible post‑notification remedies before escalating to Phase II, creating an important window for early negotiation of PCC undertakings in the Philippines.

Remedy Negotiation and Conditional Clearances

Where competition concerns are identified but appear addressable without a full Phase II investigation, the PCC and the parties may negotiate undertakings during or immediately after Phase I. The PCC’s published guidelines for merger remedies outline the types of commitments it will consider, including behavioural commitments (such as non‑discrimination, access and pricing undertakings), structural remedies (divestitures) and hold‑separate obligations. If the parties and the PCC reach agreement on adequate remedies, the PCC issues a conditional clearance decision specifying the undertakings, compliance timelines and monitoring arrangements. If no agreement is reached, or if the competitive concerns are too complex or severe, the PCC refers the case to Phase II for a full investigation.

PCC Powers: Undertakings, Conditional Approvals, Hold‑Separate & Blocking

The PCA and its IRR grant the PCC broad powers to shape the conditions under which a merger may proceed. Understanding the full range of these powers is critical for deal teams assessing closing risk and structuring transaction documents.

Common Forms of PCC Undertakings

PCC undertakings generally fall into two categories. Behavioural undertakings require the merged entity to act, or refrain from acting, in specified ways, such as maintaining supply to third‑party customers on non‑discriminatory terms, licensing intellectual property at fair, reasonable and non‑discriminatory rates or refraining from tying or bundling products in the affected market. Structural undertakings require changes to the merged entity’s assets or business scope, typically through divestiture of overlapping business units, production facilities or product lines to a PCC‑approved purchaser within a defined timeframe.

Hold‑Separate Obligations

Hold‑separate obligations are interim measures requiring the parties to maintain the target business as a separate, independent entity pending completion of a structural remedy or the PCC’s final decision. They are designed to preserve the competitive status quo and prevent irreversible integration. In practice, hold‑separate obligations demand significant operational discipline, separate management, ring‑fenced information flows and independent commercial decision‑making, and deal teams must plan for these costs and operational complexities at the transaction structuring stage.

Blocking and Injunction Risk

Where remedies are insufficient to address a substantial lessening of competition, the PCC retains the power to prohibit the transaction entirely. Additionally, the PCC may seek injunctive relief from the courts to prevent closing while a review is ongoing. The enforcement risk from the PCC therefore extends beyond financial penalties to outright deal failure, making early and proactive pre‑notification engagement with the PCC advisable for complex or concentrated markets.

PCC Clearance Timeline: Key Deadlines and Practical Timing Risks

One of the most common questions from deal teams concerns timing: how long will the PCC review take, and what drives delay? The table below maps each review stage to the PCC’s procedural framework and the commercial timeframes typically observed in practice.

Mitigation tactics to shorten the PCC clearance timeline:

• Pre‑notification engagement. Engage the MAO informally before filing to identify likely information requests, discuss market definition and gauge the PCC’s preliminary view on competitive effects.
• Front‑load data. Submit comprehensive market data, competitor analysis and customer lists with the initial notification to reduce stop‑the‑clock requests.
• Proactive remedy offers. If competition concerns are foreseeable, include a remedy proposal with the filing or early in Phase I to accelerate negotiation.
• Designate a single point of contact. Streamline communication between the deal team, external counsel and the MAO to avoid delays caused by miscommunication.

Managing Closing Risk: Conditional Closings, Escrow, Holdbacks & W&I

The interval between PCC filing and clearance exposes both buyers and sellers to material closing risk. Managing that risk requires careful structuring of transaction documents, particularly conditions precedent, escrow mechanics, holdback provisions and warranty & indemnity (W&I) insurance carveouts. This section provides drafting PCC undertakings into practical commercial protections.

Conditional Closings vs Pre‑Clearance Closing

Philippine merger control is a suspensory regime: parties may not close before obtaining PCC clearance (or the expiry of the applicable waiting period without a PCC challenge). In practice, this means the share‑purchase agreement or asset‑purchase agreement should include PCC clearance as an express condition precedent. The key negotiation point is the long‑stop date, the date by which all conditions (including PCC clearance) must be satisfied, failing which either party may terminate. Industry observers recommend setting the long‑stop date at a minimum of six months from filing, with an automatic extension of 90 days in the event Phase II is initiated.

Escrow and Escrow Triggers

Where PCC clearance is conditional on remedies (e.g., divestiture of a business unit), an escrow mechanism linked to remedy compliance protects both parties. Buyers should negotiate escrow amounts calibrated to the estimated cost of the remedy, typically 5–15 per cent of the purchase price for structural remedies, or a lower percentage for behavioural commitments. Escrow release should be tiered: partial release on PCC acceptance of the initial remedy plan, further release on completion of the divestiture or behavioural milestone, and final release after the PCC confirms full compliance with the undertaking. Both parties should agree on an independent escrow agent and clearly specify the triggers and timeline for release.

Material Adverse Change and Termination Drafting

Deals subject to PCC undertakings should include a regulatory MAC clause, a material adverse change provision specifically addressing scenarios in which the PCC imposes conditions materially more onerous than anticipated. This clause gives the buyer the right to terminate if, for example, the PCC requires divestiture of a business unit representing more than a defined percentage of EBITDA or revenue. Sellers will resist an overly broad regulatory MAC; the negotiation lever is agreeing on a quantitative materiality threshold above which the buyer may walk, while below which the parties are committed to completing the deal and performing the undertaking.

Closing‑risk negotiation checklist (key items):

• Long‑stop date with Phase II extension option.
• PCC clearance as express condition precedent.
• Escrow size, triggers and release mechanics linked to remedy milestones.
• Regulatory MAC clause with quantitative materiality threshold.
• W&I insurance carveout for regulatory non‑clearance or remedy costs exceeding a defined cap.
• Interim covenant requiring cooperation with PCC information requests.

Drafting PCC Undertakings & Model Hold‑Separate Clause: Practical Templates

This section provides three sample clauses that deal teams can adapt to their specific transaction. Each clause is preceded by drafting notes and negotiation levers. These are sample language only, they must be adapted to the specific transaction, reviewed by Philippine‑qualified counsel and tailored to any PCC conditions imposed during the review process.

Model Clause A: Behavioural Undertaking

Drafting notes: Behavioural undertakings typically address conduct in the market rather than structural changes. They are time‑limited and must be capable of effective monitoring. Negotiation levers include duration (shorter is better for the merged entity), scope (narrow product/geographic market), reporting frequency and exit ramps (automatic termination on market entry by a new competitor).

Sample language:

“The Merged Entity undertakes that, for a period of [3/5] years from the Effective Date, it shall: (a) continue to supply [Product/Service] to all existing customers on terms no less favourable than those prevailing immediately prior to Closing, adjusted only for bona fide changes in input costs; (b) refrain from tying or bundling [Product A] with [Product B] in the [Relevant Geographic Market]; and (c) submit semi‑annual compliance reports to the PCC in the form prescribed by the PCC’s guidelines for merger remedies, within 30 days of each reporting period end.”

Model Clause B: Structural / Divestiture Commitment

Drafting notes: Structural remedies are more intrusive and typically non‑reversible. Key negotiation points include the scope of the divestiture package (assets, contracts, employees, IP), the timeline for completion, the identity and qualification requirements of the purchaser, and any upfront‑buyer requirement (whereby the PCC will not clear the merger until a qualifying purchaser has been identified). Sellers should negotiate the right to propose the divestiture purchaser, subject to PCC approval.

Sample language:

“The Notifying Parties commit to divest the Divestiture Business, comprising [describe assets, contracts, key employees and IP], to a Qualifying Purchaser approved by the PCC within [6/12] months of the Clearance Date. The Notifying Parties shall: (a) appoint a Divestiture Trustee, acceptable to the PCC, to oversee the sale process and ensure the Divestiture Business is maintained as a going concern pending completion; (b) grant the Qualifying Purchaser access to all records and personnel reasonably necessary to operate the Divestiture Business; and (c) notify the PCC of the proposed Qualifying Purchaser not less than [30] days prior to the anticipated completion of the divestiture.”

Model Clause C: Hold‑Separate / Interim Management Arrangement

Drafting notes: Hold‑separate clauses preserve the target’s competitive independence during the remedy period. They require operational separation, separate management, ring‑fenced IT systems, independent pricing and restricted information sharing. Buyers resist overly prescriptive hold‑separates because they increase integration costs; sellers want clear scope limitations and defined expiry events.

Sample language:

“Pending completion of the Divestiture or final PCC determination, the Acquiring Party shall maintain the Target Business as a separate, independently managed going concern.

Without limiting the generality of the foregoing, the Acquiring Party shall: (a) appoint a Hold‑Separate Manager, who shall not be an officer, employee or agent of the Acquiring Party’s existing competing business, to manage the Target Business’s day‑to‑day operations; (b) ensure that no competitively sensitive information of the Target Business is shared with the Acquiring Party’s competing business, and vice versa; (c) maintain the Target Business’s existing customer contracts, supplier relationships and key personnel on terms substantially equivalent to those prevailing at Closing; and (d) submit quarterly reports to the PCC on the operation of the hold‑separate arrangement.

Monitoring, Enforcement Risk & Post‑Clearance Compliance

Clearance, even conditional clearance, is not the end of the story. The PCC actively monitors compliance with the undertakings it imposes, and failure to comply can result in administrative penalties, reopening of the merger review and even unwinding of the transaction. The OECD’s 2023 assessment of merger control in the Philippines highlighted the importance of effective remedy monitoring as a core component of a mature competition regime.

Reporting Templates and Timelines

Under the PCC’s guidelines for merger remedies, parties subject to undertakings must submit compliance reports at intervals specified in the clearance decision, typically quarterly for the first year and semi‑annually thereafter. Reports should detail the steps taken to implement the remedy, any deviations from the undertaking and any material changes in market conditions relevant to the remedy’s effectiveness. Deal teams should establish an internal compliance register at closing, assign a compliance officer responsible for PCC reporting and build reporting deadlines into the post‑merger integration project plan.

Common Enforcement Triggers and Penalties

The enforcement risk from the PCC is real and growing. Common triggers for enforcement action include:

• Late or incomplete compliance reports. Even administrative failures can trigger a formal inquiry.
• Premature integration. Integrating the target business before completing a required divestiture or before the hold‑separate period ends is treated as a breach of the undertaking.
• Failure to divest on time. If the divestiture deadline passes without completion, the PCC may appoint a divestiture trustee with authority to sell the assets at any price necessary to complete the remedy.
• Gun‑jumping. Closing before PCC clearance is obtained, or before the applicable waiting period expires, is a separate offence under the PCA carrying significant fines.

Managing Multi‑Agency Monitoring

Many Philippine M&A transactions also require clearance from sector‑specific regulators, for example, the Securities and Exchange Commission (SEC) for corporate restructurings, the Bangko Sentral ng Pilipinas for banking and financial services, or the National Telecommunications Commission for telecoms. Deal teams should map all applicable regulatory approvals at the outset, sequence filings to avoid conflicting remedy obligations, and consider whether undertakings offered to the PCC are consistent with requirements likely to be imposed by sectoral regulators. Where a party needs to register a local branch or file SEC forms, the compliance timelines should be coordinated with PCC remedy milestones.

Practical Remedy Negotiation Checklist

The checklist below consolidates the key action items across the PCC notification and remedy lifecycle. Deal teams should assign each item to a responsible party and track completion against the deal timetable.

Pre‑filing

• Conduct preliminary competition assessment (market definition, overlaps, HHI).
• Engage PCC informally for pre‑notification discussion if the deal is complex or involves concentrated markets.
• Prepare complete notification package with market data and supporting evidence.
• Identify foreseeable PCC concerns and develop a preliminary remedy proposal.

Filing day

• Confirm filing completeness against PCC Merger Procedure Rules checklist.
• Designate single point of contact for MAO communications.
• Circulate internal timeline showing statutory deadlines and deal long‑stop date.

Post‑filing negotiation priorities

• Respond to PCC information requests within shortest practicable timeframe to avoid clock‑stop delays.
• Track Phase I review timeline and prepare for potential remedy negotiation window.
• Evaluate remedy options (behavioural vs structural) against deal economics and integration plan.
• Draft undertaking clauses using model templates; negotiate scope, duration and reporting cadence.
• If Phase II is initiated, reassess long‑stop date and escrow mechanics.

Closing

• Confirm PCC clearance decision (unconditional or conditional) is received and final.
• Execute escrow release mechanics if conditional clearance with remedy milestones.
• Establish post‑merger compliance register and assign compliance officer for PCC reporting.
• Coordinate with SEC and sectoral regulators on any parallel post‑closing filings.
• If closing involves winding down a Philippine entity, align with PCC remedy timelines.

Conclusion & Recommended Next Steps

Managing PCC undertakings in the Philippines after notification requires a disciplined combination of regulatory expertise, transaction structuring and operational planning. The three critical takeaways from this guide are: first, engage the PCC early, pre‑notification engagement and front‑loaded data substantially reduce review timelines and Phase II referral risk. Second, build PCC risk into your deal documents from day one, long‑stop dates, escrow mechanics, regulatory MAC clauses and W&I carveouts must reflect the realistic range of PCC outcomes. Third, treat clearance as the start of the compliance lifecycle, not the end, post‑clearance monitoring, reporting and multi‑agency coordination are essential to avoiding enforcement action. For complex cross‑border transactions or deals involving concentrated Philippine markets, early engagement with qualified M&A counsel is strongly recommended.

Practitioners can find experienced Philippines M&A advisers through the Global Law Experts directory.

Sources

1. Philippine Competition Commission, About the PCC
2. PCC Merger Procedure Rules (PDF)
3. PCC, Guidelines for Merger Remedies
4. PCC, Adjusted Merger Notification Thresholds Effective March 2026
5. Implementing Rules and Regulations of the Philippine Competition Act (Republic Act No. 10667)
6. OECD, Assessment of Merger Control in the Philippines (2023)